These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 19670415)

  • 1. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.
    Macías J; Berenguer J; Japón MA; Girón JA; Rivero A; López-Cortés LF; Moreno A; González-Serrano M; Iribarren JA; Ortega E; Miralles P; Mira JA; Pineda JA
    Hepatology; 2009 Oct; 50(4):1056-63. PubMed ID: 19670415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients.
    Sagnelli C; Uberti-Foppa C; Galli L; Pasquale G; Coppola N; Albarello L; Doglioni C; Lazzarin A; Sagnelli E
    Braz J Infect Dis; 2014; 18(2):164-9. PubMed ID: 24650995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
    Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
    HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
    Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
    Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.
    Benhamou Y; Di Martino V; Bochet M; Colombet G; Thibault V; Liou A; Katlama C; Poynard T;
    Hepatology; 2001 Aug; 34(2):283-7. PubMed ID: 11481613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C).
    Sherman KE; Andersen JW; Butt AA; Umbleja T; Alston B; Koziel MJ; Peters MG; Sulkowski M; Goodman ZD; Chung RT;
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):597-605. PubMed ID: 20921898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C.
    Labarga P; Fernández-Montero JV; de Mendoza C; Barreiro P; Soriano V
    Antivir Ther; 2015; 20(1):65-72. PubMed ID: 25105286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
    PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era.
    Sanmartin R; de Felipe E; Tor J; Sanvicens A; Barluenga E; Martinez E; Muga R; Jou A; Ojanguren I; López JJ; Clotet B; Tural C
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1235-43. PubMed ID: 22443303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
    Bani-Sadr F; Lapidus N; Bedossa P; De Boever CM; Perronne C; Halfon P; Pol S; Carrat F; Cacoub P; ;
    Clin Infect Dis; 2008 Mar; 46(5):768-74. PubMed ID: 18248298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis.
    Martín-Carbonero L; Tuma P; Vispo E; Medrano J; Labarga P; González-Lahoz J; Barreiro P; Soriano V
    J Viral Hepat; 2011 Aug; 18(8):542-8. PubMed ID: 20819149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
    Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
    Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Duclos-Vallée JC; Féray C; Sebagh M; Teicher E; Roque-Afonso AM; Roche B; Azoulay D; Adam R; Bismuth H; Castaing D; Vittecoq D; Samuel D;
    Hepatology; 2008 Feb; 47(2):407-17. PubMed ID: 18098295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
    Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA
    Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained virological response according to the type of early virological response in HCV and HCV/HIV.
    Lerias de Almeida PR; Alves de Mattos A; Valle Tovo C
    Ann Hepatol; 2010; 9(2):150-5. PubMed ID: 20526007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
    Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus.
    Ryan P; Resino S; Miralles P; Cosín J; López JC; Moreno S; Catalán P; Ramírez M; Gutiérrez I; Berenguer J
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):176-81. PubMed ID: 20577091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic issues in HIV/HCV-coinfected patients.
    Sulkowski MS; Benhamou Y
    J Viral Hepat; 2007 Jun; 14(6):371-86. PubMed ID: 17501757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
    Maida I; Martin-Carbonero L; Sotgiu G; Vispo E; Barreiro P; Gonzalez-Lahoz J; Soriano V
    J Viral Hepat; 2010 Dec; 17(12):866-71. PubMed ID: 20088891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
    Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
    HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.